Merck Launches Ontruzant (biosimilar- trastuzumab) in the US
Shots:
- Merck reports the launch of Ontruzant (trastuzumab-dttb)- a biosimilar referencing Herceptin and will be available in both 150mg single-dose vials at a WAC of ~$1-325 and 420mg multiple-dose vials at a WAC of ~ $3-709- representing a 15% discount to the current list price of Herceptin
- The biosimilar is being launched as a part of a development and commercialization agreement with Samsung Bioepis- under which Merck has right to commercialize the therapy in licensed territories- including the US while Samsung Bioepis is responsible for pre/clinical development- manufacturing- CTs and regulatory registration
- Ontruzant showed high bio-similarity to Herceptin in terms of safety- purity and potency of therapy and received the FDA’s approval in Jan’2019. Merck will support the commercialization of Ontruzant until the spinoff- which expected to take place in H1’21
Click here to read full press release/ article
Ref: Merck | Image: Merck
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com